Basilea Pharmaceutica Announces the Submissions of Marketing Authorization Applications in the EU for Alitretinoin, an Investigational Drug for the Treatment of Severe Refractory Chronic Hand Eczema

Basel, Switzerland, September 11, 2007 - Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) announced today the submissions of Marketing Authorization Applications (MAA) under the decentralized procedure to various EU member states for alitretinoin. These submissions support the proposed use of oral alitretinoin in severe refractory chronic hand eczema.